Immuneering Corporation - Class A Common Stock (NQ:IMRX)

4.400 +0.230 (+5.52%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 4, 2026 Add to My Watchlist

Price and Volume

Volume	764,820
Open	4.220
Bid (Size)	4.290 (200)
Ask (Size)	4.400 (5,000)
Prev. Close	4.170
Today's Range	4.200 - 4.410
52wk Range	2.900 - 10.08
Shares Outstanding	25,938,064
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition

July 21, 2026

From Immuneering Corporation

Via GlobeNewswire

Immuneering Corporation Announces Grants of Inducement Awards

July 17, 2026

From Immuneering Corporation

Via GlobeNewswire

Performance

YTD	-33.5%	-33.5%
1 Month	-14.4%	-14.4%
3 Month	-18.3%	-18.3%
6 Month	-8.7%	-8.7%
1 Year	+28.3%	+28.3%

More News

Immuneering Appoints Andrew Gengos as Chief Financial Officer

June 15, 2026

From Immuneering Corporation

Via GlobeNewswire

IMRX Stock Closed Over 20% Higher Today: Here’s Why ↗

January 07, 2026

Via Stocktwits

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

June 11, 2026

From Immuneering Corporation

Via GlobeNewswire

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

June 01, 2026

From Immuneering Corporation

Via GlobeNewswire

Friday's session: gap up and gap down stocks ↗

May 22, 2026

Via Chartmill

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

May 21, 2026

From Immuneering Corporation

Via GlobeNewswire

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

May 15, 2026

From Immuneering Corporation

Via GlobeNewswire

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

April 21, 2026

From Immuneering Corporation

Via GlobeNewswire

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

April 20, 2026

From Immuneering Corporation

Via GlobeNewswire

Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference

April 06, 2026

From Immuneering Corporation

Via GlobeNewswire

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival

March 17, 2026

From Immuneering Corporation

Via GlobeNewswire

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

March 06, 2026

From Immuneering Corporation

Via GlobeNewswire

Immuneering to Present at the Leerink Global Healthcare Conference

March 02, 2026

From Immuneering Corporation

Via GlobeNewswire

Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 18, 2026

From Immuneering Corporation

Via GlobeNewswire

Here are the top movers in Thursday's session. ↗

January 08, 2026

Via Chartmill

These stocks are gapping in today's session ↗

January 08, 2026

Via Chartmill

Get insights into the top gainers and losers of Thursday's pre-market session. ↗

January 08, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's after-hours session. ↗

January 07, 2026

Via Chartmill

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

January 07, 2026

From Immuneering Corporation

Via GlobeNewswire

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

December 23, 2025

From Immuneering Corporation

Via GlobeNewswire

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

December 17, 2025

From Immuneering Corporation

Via GlobeNewswire

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

December 16, 2025

From Immuneering Corporation

Via GlobeNewswire

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

November 25, 2025

From Immuneering Corporation

Via GlobeNewswire

Frequently Asked Questions

Is Immuneering Corporation - Class A Common Stock publicly traded?

Yes, Immuneering Corporation - Class A Common Stock is publicly traded.

What exchange does Immuneering Corporation - Class A Common Stock trade on?

Immuneering Corporation - Class A Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Immuneering Corporation - Class A Common Stock?

The ticker symbol for Immuneering Corporation - Class A Common Stock is IMRX on the Nasdaq Stock Market

What is the current price of Immuneering Corporation - Class A Common Stock?

The current price of Immuneering Corporation - Class A Common Stock is 4.400

When was Immuneering Corporation - Class A Common Stock last traded?

The last trade of Immuneering Corporation - Class A Common Stock was at 08/04/26 04:00 PM ET

What is the market capitalization of Immuneering Corporation - Class A Common Stock?

The market capitalization of Immuneering Corporation - Class A Common Stock is 114.13M

How many shares of Immuneering Corporation - Class A Common Stock are outstanding?

Immuneering Corporation - Class A Common Stock has 114M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.